ArticleInternational journal of clinical oncology2026
Impact of prior PARP inhibitor exposure on the efficacy of platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer: a propensity score-matched analysis.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the efficacy of platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer (PSROC) between patients with and without prior exposure to poly(ADP-ribose) polymerase inhibitor (PARPi).
methodsPatients with PSROC treated at Jichi Medical University Hospital between January 2010 and December 2024 were retrospectively reviewed. Post-PARPi and PARPi-naïve patients were extracted from 2018 to 2024 (post-market of PARPi) and 2010 to 2017 (pre-market of PARPi), respectively, and subjected to 1:1 propensity score matching. The response rate, progression-free survival (PFS), and overall survival (OS) were analyzed.
resultsThe matched cohort included 22 patients in each group. After matching, the objective response rate was lower in the post-PARPi group than in the PARPi-naïve group (59.1% vs. 86.4%), although the difference was not statistically significant (p = 0.088). Before matching, both PFS (7.1 vs. 12.0 months, p = 0.005) and OS (22.1 vs. 43.8 months, p = 0.001) were significantly shorter in the post-PARPi group. After matching, PFS (7.0 vs. 12.4 months, p = 0.069) and OS (15.4 vs. 33.6 months, p = 0.091) remained numerically shorter. On multivariate analysis, response at prior PARPi initiation (partial vs. complete response) and the status of PARPi use at recurrence (on PARPi vs. after PARPi therapy) were independent predictors for PFS among post-PARPi patients, whereas the platinum-free interval did not independently predict prognosis.
conclusionsPrior PARPi exposure, particularly partial response to platinum at the start of prior PARPi therapy and recurrence on PARPi therapy, may be associated with reduced platinum efficacy and worse prognosis in PSROC.
Indexed as
Identifiers
41882282What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.